Shots:

• The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739 patients with active PsA including those previously treated with a biologic anti-TNF alpha agent
• The results showed that Tremfya inhibited radiographic progression & maintained low rates of progression @ 2yrs. in biologic-naïve patients, improvements in joints, axial symptoms, enthesitis, dactylitis & an improvement in pain with 32% & 33% of patients achieved =20% & =50 % improvement @16wks.
• The safety profile was consistent b/w adults with active PsA @ 2yrs. & adults with PsO through 5yrs. The therapy is approved in the US, Canada, Japan, & other countries globally for plaque PsO & active PsA

  Ref: PR Newswire | Image: Janssen